Philadelphia, PANCT06193889Now EnrollingIRB Ready

Myasthenia Gravis Clinical Trial in Philadelphia, PA

Access cutting-edge myasthenia gravis treatment through this phase 2/3 clinical trial at a research site in Philadelphia. Study-provided care at no cost to qualified participants.

Sponsored by Kyverna Therapeutics

Quick Self-Assessment

See if you qualify for this Philadelphia location

Preparing your pre-screening questions…

Expert Care in Philadelphia

Access myasthenia gravis specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related myasthenia gravis treatment provided free

Apply for This Philadelphia Location

Check if you qualify for this myasthenia gravis clinical trial in Philadelphia, PA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Philadelphia

    Convenient for PA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Philadelphia site if eligible
  4. 4Begin participation

About This Myasthenia Gravis Study in Philadelphia

A Study of the Anti-CD 19 Chimeric Antigen Receptor T Cell Therapy for Patients with Myasthenia Gravis

Sponsor: Kyverna Therapeutics

Who Can Participate

Inclusion Criteria

Presence of autoantibodies to AChR or MuSK
Myasthenia Gravis Foundation of America (MGFA) Class II-IV
MG-Activities of Daily Living (MG-ADL) total score of ≥6 at screening and confirmed at baseline visit
QMG total score of ≥11 at screening an confirmed at baseline visit
Failed treatment with 2 or more immunosuppressive/immunomodulatory therapies, or failed at least 1 immunosuppressive therapy and required chronic plasmapheresis, or IVIG (or subcutaneous or intramuscular Ig) to control symptoms
On a stable dose of glucocorticoids and/or other immunotherapies for ≥1 month prior to screening. For patients treated with azathioprine, a stable dose for ≥2 months prior to screening is required
No change in dose of acetylcholinesterase inhibitors for ≥2 weeks prior to screening
No use of intravenous immune globulin (IVIG) or plasmapheresis (PLEX) within 4 weeks of screening or pre-dose baseline (unless this is part of their SOC treatment regimen)
No use of rituximab (or any other anti-CD20 or CD19 monoclonal antibody) within 12 weeks prior to screening
Able and willing to attend the necessary visits to the study site Key

Exclusion Criteria

Unable to washout or interrupt autoimmune disease therapy prior to apheresis and/or baseline if required
Co-occurring neurological autoimmune disease (ie, Lambert-Eaton Myasthenic Syndrome) or any disease affecting the neuromuscular junction or muscle causing weakness (eg, myositis, myopathy, motor neuropathy)
History of stroke (with residual sequalae and/or risk for recurrence), seizure (even if well controlled on antiepileptics), neurodegenerative disease, altered mental status (unexplained and/or recent/current), or uncontrolled/severe psychiatric disease
Any serious and/or uncontrolled medical condition that, in the investigator's judgment, would cause unacceptable safety risk, interfere with study procedures or results, or compromise compliance with the protocol, including but not limited to, clinically significant cardiac or pulmonary disease
History of primary immunodeficiency, organ or allogeneic bone marrow transplant, or splenectomy
Active, uncontrolled, viral, bacterial, or systemic fungal infection or recent history of repeated infections
Thymectomy \<12 months of screening or planned during the study
Prior treatment with gene therapy product or cellular immunotherapy (eg, CAR T) requiring vector integration and directed at any target
Patients requiring chronic anticoagulation therapy that cannot be discontinued for medical procedures

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Philadelphia?

Yes, this clinical trial (NCT06193889) has an active research site in Philadelphia, PA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Myasthenia Gravis Treatment Options in Philadelphia, PA

If you're searching for myasthenia gravis treatment options in Philadelphia, PA, this clinical trial (NCT06193889) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Philadelphia research site is actively enrolling participants for this phase 2/3 clinical trial. You'll receive care from experienced myasthenia gravis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all myasthenia gravis clinical trials near you to find additional studies recruiting in your area.

More Myasthenia Gravis Trials in Philadelphia, PA

See all myasthenia gravis clinical trials recruiting in Philadelphia — not just this study.

Browse Myasthenia Gravis Trials in Philadelphia →

Browse More Trials by Condition

Myasthenia Gravis TrialsRheumatoid Arthritis TrialsAnkylosing Spondylitis TrialsAll Conditions →

Ready to Join in Philadelphia?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Philadelphia, PA